IXIARO JAPANESE ENCEPHALITIS VALNEVA

Privacy Policy

Last Updated: September 2023
Valneva SE and its affiliates (“Valneva“, “we“, “us” or “our“) have created this privacy policy (hereafter referred to as the “Privacy Policy“) to demonstrate our firm commitment to privacy. The following discloses our processing of personally identifiable information (“Personal Information”) in accordance with applicable law, including Canada’s Personal Information Protection and Electronic Documents Act (“PIPEDA”), Québec’s Act respecting the protection of personal information in the private sector, and the European Regulation (EU) 2016/679, “GDPR”, with regard to the use of our website and several listed aspects, for example, pharmacovigilance or customer data.
This Privacy Policy applies to individuals we deal with including consumers, patients, health care professionals, and others within the health care or pharmaceutical industries (“you” or “your”), and explains how we collect, use, disclose and otherwise process and protect your Personal Information. This Privacy Policy further includes a description of your privacy rights.

Use of the Websites

Our websites and the subsites may collect and process data regarding your behavior on our website in accordance with this Privacy Policy and with your consent, where required. If you do not agree to the collection, use and disclosure of your Personal Information in this way, please do not use the websites or provide us with Personal Information.
The websites may collect information from visitors both by asking you specific questions and by permitting you to communicate directly with us via email and/or feedback forms. Some of the information that you submit on the website may be Personal Information. A website may further use “cookies” and Internet Protocol (“IP”) addresses. A cookie is a bit of information that a website sends to your web browser that helps the website remember information about you and your preferences and an IP address is a number assigned to your computer by your Internet service provider. The IP address can be used to diagnose problems with a server, report aggregate information, determine the fastest route for your computer to use in connecting to a website, and administer and improve the website.
Google Analytics: Our websites uses Google Analytics, a web analytics service provided by Google, Inc. (“Google”). Google Analytics uses cookies to help the website analyse how users use the website. The information generated by the cookie about your use of this website is usually transmitted to a Google server in the USA and stored there. Valneva has activated IP anonymization on its websites, therefore, your IP address will be truncated beforehand by Google within applicable jurisdictions.
Only in exceptional cases the full IP address might be transmitted to a Google server in the USA and shortened there. On behalf of the operator of this website, Google will use this anonymized information for the purpose of evaluating the use of the website, compiling reports on website activity and providing other services relating to website activity and internet usage to the website operator. The IP address transmitted by your browser as part of Google Analytics will not be merged with other data from Google. You may refuse the use of cookies by selecting the appropriate settings on your browser, however, please note that if you do this you may not be able to use the full functionality of this website. You can also prevent the collection of data generated by the cookie and related to your use of the website (including your IP address) to Google and the processing of this data by Google by downloading and installing the browser plugin available at the following link  (http://tools.google.com/dlpage/gaoptout?hl=de). We would like to point out that on our websites Google Analytics has been extended by the code “anonymizeIp” in order to ensure anonymized collection of IP addresses (so-called IP masking).
Please note that if you wish to subscribe and connect your personal social media account to our website, e.g. if you would like to share information on your own social media account, certain Personal Information will be shared with us such as Personal Information linked to your profile or your friends’ profiles on the applicable social media account.

Pharmacovigilance

Pharmacovigilance is the process of discovering, evaluating, understanding, and preventing adverse reactions or other problems related to medicines. Their notification is of great importance for public health. We will only use and share this information for pharmacovigilance purposes. This processing is necessary for compliance with a legal obligation to which Valneva is subject. Valneva is required to store and report information relevant to pharmacovigilance to health authorities worldwide (including countries whose privacy laws differ from those of your local jurisdiction). The reports contain detailed information on the incident, but only to a limited extent Personal Information.
Concerning patients, the notification will contain, if available, only age, date of birth, year of birth, gender, and initials, depending on the information available, but never the name of the patient. With regard to the person reporting a potential adverse reaction, the notification will include, depending on the information available, the name, professional activity (e.g. doctor, pharmacist), address, e-mail address, and telephone number. The contact details are necessary to be able to follow up the reporting and thus obtain high-quality and complete information on adverse events. Information on notifications will be kept for at least ten (10) years after the product is no longer on the market in any country.

Recruitment

We will store and process your data for the purpose of your application based on your consent and in accordance with applicable law.
We will forward your Personal Information and the attachments you provided to the respective country organization with applicable open job opportunities. We will keep your Personal Information in evidence for filling additional positions for a maximum period of seven months from the date of the receipt of your application. Your Personal Information will be kept strictly confidential, will not be passed on to any other companies except Valneva country organizations with applicable open job opportunities and will only be passed on within the company to the heads of departments where a suitable position is available.
Your personal Information will be deleted automatically after twelve (12) months from the date of receipt of your application. You can revoke your consent to Personal Information processing at any time in writing via gdpr@valneva.com. In this case, please refer to your job application and we will delete your Personal Information.

Vendor, customer or other business partners

We will not use your Personal Information for marketing activities unless you have consented to receive marketing communications from us. Based either on consent or, when applicable, on the fulfilment of contractual obligations, we will store your name, contact details, and your position within your company being a vendor, customer, or other business partners. Based on your consent, we will publish your Information as a health care professional on our website www.reisemedizincheck.at (for Austria) or www.bewareofthebugs.com (for United Kingdom).

Medical Requests

Your medical requests regarding our products will be stored due to legal obligations and in the legitimate interests of Valneva to have evidence about the information provided when replying to medical requests. We will store your name, contact details, the content of your request, and the content of our reply to your request. We will store this Information for 30 years after having received your medical request.

Security

We take reasonable steps to protect your Personal Information using physical (locked filing cabinets and restricted access to offices), electronic (especially firewalls), or procedural security measures appropriate to the sensitivity of the information. Valneva will take appropriate steps to ensure that Personal Information about you is protected from loss or theft, as well as unauthorized access, disclosure, copying, use, or modification.
Although we have enacted security measures, we cannot guarantee the security of any information that you submit via email or over the Internet. To the extent permitted under applicable law, we make no warranty, express or implied, concerning the security or integrity of any Personal Information. You submit your Personal Information using such networks at your own risk since no Internet transmission is ever 100% secure or error-free (in particular, emails sent to or from the website may not be secure). You should take special care in deciding what information you send to us via email or posting on the website. Moreover, where you use passwords, ID numbers, or other special access features on the website, it is your responsibility to safeguard them.

Links to other Websites

The website may contain links or references to other websites to which this Privacy Policy does not apply. Valneva is not responsible for the data collection and use practices of companies or organizations to which the website may provide links. We encourage you to read the privacy statement/policy of every website you visit.
Valneva makes no representations whatsoever about any other website which you may access through this website. Besides, a link to a website does not mean that Valneva endorses or accepts any responsibility for the content, or the use, of such website.

Transfer of Personal Information

We may transfer your Personal Information to servers located outside Canada to affiliates or third parties in other countries in accordance with the terms of this Privacy Policy and applicable privacy laws. Your Personal Information may not be given the same legal protection in other countries that you may have in Canada. While your personal information is in another country, we will ensure that anyone processing your Personal Information is required to implement measures to protect it in accordance with this Privacy Policy and applicable privacy laws and regulations, including PIPEDA.

Collection of Personal Information from Children

This website is not directed to individuals under the age of sixteen (16) (or such other lower age determined by applicable laws), and we do not knowingly collect any Personal Information from children under such age. Should we need to process the Personal Information of an individual under the age of sixteen (16) (or such other lower age determined by applicable laws) consent to such processing must be given by an authorized person with parental responsibility for the child.

Privacy Policy Changes

This Privacy Policy may be revised from time to time. If we intend to use or disclose Personal Information for purposes materially different than those described in this Privacy Policy, we will make reasonable efforts to notify affected individuals, if necessary, including by posting the revised Privacy Policy on this website. We recommend that you review this Privacy Policy frequently.

Information Regarding Your Rights

If you would like to access your Personal Information or get it rectified, updated, or transferred to other organizations please contact us at the address below. You also have the right to object or to restrict some processing and, where we have asked for your consent to process your Personal Data, to withdraw your consent at any time and we will stop any future use of your Personal Information (unless there is a legitimate interest and/or legal obligation that prevents us from doing so). We may request a reasonable fee for administering certain requests. Authorized employees, agents, and representatives of Valneva who require access to your Personal Information to fulfill their job requirements will have access to your Personal Information.
You may contact us by writing to us at the following address:
Valneva Canada Inc. Commercial Operations 3535 Saint-Charles Blvd., Suite 600 Kirkland (Québec) H9H 5B9, Canada.
You may also contact Valneva’s Data Protection Officer Stephan Gold via the following contact details:
Valneva Austria GmbH
Campus Vienna Biocenter 3
A-1030 Vienna
Austria, Europe
E-mail: gdpr@valneva.com,
Fax +43 1 20 620 800
NOTE: If you are a physician or other healthcare professional and would like to record an adverse event, please fill out the form to help process your information quickly and effectively.

Contact the Supervisory Authority

If you have any comments or complaints regarding the way your Personal Information is being handled, you have the right to contact the supervisory authority in your country of residence to lodge a complaint. If you live in Canada, you may consider contacting the Office of the Privacy Commissioner of Canada (“OPC”) or the Commission d’accès à l’information du Québec:

Office of the Privacy Commissioner of Canada

Telephone: 1-800-282-1376
Website: priv.gc.ca
Write to: 30 Victoria Street Gatineau, Quebec K1A 1H3 Commission d’accès à l’information du Québec
Telephone: 418-528-7741 / 1-888-528-7741 (toll-free)
Website: https://www.cai.gouv.qc.ca
Email: cai.communications@cai.gouv.qc.ca
For Europe, please click here to obtain relevant contact information to supervisory authorities: http://ec.europa.eu/justice/article-29/structure/data-protectionauthorities/index_en.htm

I confirm I am a Canadian healthcare professional


This will close in 0 seconds

Myth: Temporal and spatial distribution of JE can be predicted


Annual incidence JE is unpredictable. The number of cases may fluctuate from year to year, from season to season and from region to region.8,14

Spatial and temporal distribution of JE cases in mainland China in 2013 and 201414

This will close in 0 seconds

Myth: Risk for JEV transmission only exists in rural areas


Besides rural areas, circulation of JEV has been demonstrated in mosquitoes within several cities in Southeast Asia.15,16

Visitors to areas where JE is endemic, or epidemic are at higher risk of being infected with JE compared to the local population.1

This will close in 0 seconds

Myth: JE only occurs in travellers staying 30 days or more in endemic countries


Symptomatic JE has occurred in travellers visiting areas for a duration of travel shorter than 1 month.3

This will close in 0 seconds

Myth: Travellers are only bitten during the rainy season


Two epidemiologic patterns of JE occur:8,11

  1. In temperate areas, JE can be transmitted sporadically with periodic seasonal epidemics (May–October)
  2. In subtropical areas, JE is endemic, and transmission can occur throughout the year

Transmission may occur year-round8,11

Environmental factors can also play a key role in mosquito-borne transmission. This is especially due to climate change, which tends to influence the mosquito density.15

This will close in 0 seconds

Seasonality by country


Country Affected areas Transmission season
Australia Outer Torres Strait Islands, parts of four states on mainland (New South Wales, Queensland, South Australia, Victoria) November–May
Bangladesh Widespread Year-round with most cases reported July–November
Bhutan Presumed widespread in nonmountainous areas Unknown
Brunei Darussalam Presumed widespread Unknown
Burma (Myanmar) Widespread Year-round with most cases reported May–September
Cambodia Widespread Year-round with peak season May–October
China All provinces except Xinjiang and Qinghai Peak season June–October
India Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Goa, Haryana, Jharkhand, Karnataka, Kerala, Maharashtra, Manipur, Meghalaya, Nagaland, Odisha, Punjab, Tamil Nadu, Telangana, Tripura, Uttar Pradesh, Uttarakhand, West Bengal Peak season May–November, especially in northern India; the season may be extended or year-round in some areas, especially in southern India
Indonesia Widespread Year-round, with peak season varying by island
Japan All islands June–October
Lao People’s Democratic Republic Widespread Year-round with peak season June–September
Malaysia Widespread Year-round, with peak season in Sarawak from October–December
Nepal Southern lowlands (Terai), some hill and mountain districts Peak season June–October
North Korea Presumed widespread Unknown
Proximity to South Korea suggests peak transmission May–November
Pakistan Unknown Unknown
Papua New Guinea Widespread Presumed year-round
Philippines Widespread Year-round with peak season April–August
Russia Primorsky Krai June–September
Singapore Presumed in focal areas Year-round
Sri Lanka Widespread except in mountainous areas Year-round with peak season
November–February
Taiwan Widespread Peak season May–October
Thailand Widespread Year-round with peak season May–October, especially in northern Thailand
Highest rates of disease reported from Chiang Mai Valley
Several traveller cases reported in recent years from resort and coastal areas of southern Thailand
Timor-Leste Presumed widespread No data
Proximity to West Timor suggests year-round
Vietnam Widespread Year-round with peak season May–October, especially in northern Vietnam
† Destination and transmission season information should be considered in association with travel duration and activities when making decisions on vaccination.13
‡ Data are based on published and unpublished reports. Risk assessments should be performed cautiously, because risk can vary within areas and from year to year, and surveillance data regarding human cases and JEV transmission are often incomplete. In some endemic areas, human cases among residents are limited because of vaccination or natural immunity among older people. However, because JEV is maintained in an enzootic cycle between animals and mosquitoes, susceptible visitors to these areas still may be at risk for infection.13
§ Outbreaks previously occurred in the Western Pacific Islands of Guam (1947–1948) and Saipan (1990), but as they are no longer considered risk areas, they are not included in the table.13

This will close in 0 seconds

Caractère saisonnier de l’encéphalite japonaise en fonction du pays


Pays Régions touchées Saison de transmission
Australie Îles du détroit de Torrès, parties de quatre États continentaux (Nouvelle-Galles du Sud, Queensland, Australie-Méridionale et Victoria) Novembre à mai
Bangladesh Transmission généralisée À l’année, mais la majorité des cas sont signalés entre juillet et novembre
Bhoutan Transmission présumée dans les régions non montagneuses Aucune donnée
Birmanie (Myanmar) Transmission généralisée À l’année; majorité des cas signalés entre mai et septembre
Brunei Darussalam Transmission généralisée présumée Aucune donnée
Cambodge Transmission généralisée À l’année; saison de pointe de mai à octobre
Chine Dans toutes les provinces sauf Xinjiang et Qinghai Saison de pointe : de juin à octobre
Corée du Nord Transmission généralisée présumée Aucune donnée
La proximité avec la Corée du Sud donne à croire que la saison de pointe est de mai à novembre
Inde Andhra Pradesh, Arunachal Pradesh, Assam, Bengale occidental, Bihar, Goa, Haryana, Jharkhand, Karnataka, Kerala, Maharashtra, Manipur, Meghalaya, Nagaland, Odisha, Pendjab, Tamil Nadu, Telangana, Tripura, Uttar Pradesh, Uttarakhand Saison de pointe : de mai à novembre, particulièrement en Inde du Nord; la saison pourrait être prolongée ou annuelle dans certaines régions, en particulier dans le sud de l’Inde
Indonésie Transmission généralisée Toute l’année; saison de pointe variable selon l’île visitée
Japon Toutes les îles Juin à octobre
Malaisie Transmission généralisée Toute l’année; saison de pointe à Sarawak d’octobre à décembre
Népal Basses-Terres du Sud (Terai), certains districts dans les collines et les montagnes Saison de pointe de juin à octobre
Pakistan Aucune donnée Aucune donnée
Papouasie-Nouvelle-Guinée Transmission généralisée Transmission toute l’année présumée
Philippines Transmission généralisée Toute l’année; saison de pointe d’avril à août
République démocratique populaire lao Transmission généralisée Toute l’année; saison de pointe de juin à septembre
Russie Kraï du Primorié De juin à septembre
Singapour De cas présumément signalés dans les secteurs d’intérêt Toute l’année
Sri Lanka Transmission généralisée sauf dans les régions montagneuses Toute l’année; saison de pointe de novembre à février
Taïwan Transmission généralisée Saison de pointe : de mai à octobre
Thaïlande Transmission généralisée Toute l’année; saison de pointe de mai à octobre, particulièrement au nord; les taux les plus élevés de maladie sont signalés dans la vallée du Chiang Mai; plusieurs cas ont récemment été signalés chez des voyageurs en visite dans les régions touristiques ou côtières de la Thaïlande du Sud
Timor-Leste Transmission généralisée présumée Aucune donnée
La proximité avec le Timor occidental donne à croire que la saison dure toute l’année
Vietnam Transmission généralisée Toute l’année; saison de pointe de mai à octobre, particulièrement au nord
† Pour décider des vaccins à administrer, on doit examiner les données concernant la destination et les saisons de transmission en fonction de la durée du voyage et des activités prévues13.
‡ Les données sont tirées de rapports publiés et non publiés. L’évaluation du risque doit s’effectuer avec prudence, car le risque peut varier à l’intérieur d’une même région et d’année en année, et parce que les données de surveillance concernant les cas chez l’humain et la transmission du virus de l’encéphalite japonaise sont souvent incomplètes. Dans certaines régions où le virus est endémique, les cas chez les résidents humains sont limités en raison de la vaccination ou de l’immunité naturelle chez les personnes âgées. Cependant, parce que le virus de l’encéphalite japonaise se maintient dans un cycle enzootique entre les animaux et les moustiques, les visiteurs susceptibles de contracter le virus qui se rendent dans ces régions pourraient être à risque d’infection13.
§ Des éclosions se sont produites dans l’île de Guam (1947-1948) et à Saipan (1990), mais ces pays ne figurent pas dans le présent tableau, car ils ne sont plus considérés comme des régions à risque13.

This will close in 0 seconds

Mythe : Les voyageurs se font piquer seulement durant la saison des pluies.


Le tableau épidémiologique de l’encéphalite japonaise est double8,11 :

  1. Dans les régions tempérées, l’encéphalite japonaise peut se transmettre de manière sporadique avec des épidémies saisonnières périodiques (de mai à octobre).
  2. Dans les régions subtropicales, l’encéphalite japonaise est endémique; la transmission peut survenir à tout moment de l’année.
 

La transmission peut survenir toute l’année8,11.

 

Les facteurs environnementaux peuvent également jouer un rôle important dans la transmission des maladies par les moustiques. Ceci est particulièrement vrai en contexte de changement climatique susceptible d’influencer la densité des moustiques15.

This will close in 0 seconds

Mythe : L’encéphalite japonaise ne survient que chez les voyageurs qui séjournent durant 30 jours et plus dans les pays où le virus est endémique.


L’encéphalite japonaise symptomatique est survenue chez des voyageurs qui ont séjourné moins de 1 mois dans des régions à risque3.

This will close in 0 seconds

Mythe : Le risque de transmission du virus de l’encéphalite japonaise n’existe que dans les régions rurales.


La présence du virus de l’encéphalite japonaise dans des moustiques a été démontrée non seulement dans les régions rurales, mais aussi dans plusieurs villes de l’Asie du Sud-Est15,16.

Les visiteurs qui se rendent dans les endroits où l’encéphalite japonaise est endémique ou épidémique sont à risque plus élevé de contracter une infection au virus de l’encéphalite japonaise comparativement à la population locale1 .

This will close in 0 seconds

Mythe : La distribution chronologique et géographique de l’encéphalite japonaise est prévisible.


L’incidence annuelle de l’encéphalite japonaise est imprévisible. Le nombre de cas pourrait varier d’année en année, de saison en saison et de région en région8,14.

Distribution géographique et chronologique des cas d’encéphalite japonaise en Chine continentale en 2013 et 201414

 

This will close in 0 seconds

Je confirme que je suis un professionnel de la santé canadien


This will close in 0 seconds

Déclarer une réaction indésirable pouvant être liée au médicament


This will close in 0 seconds

Report a possible adverse drug reaction


This will close in 0 seconds

I am a Canadian resident.


This will close in 0 seconds

Je réside au Canada.


This will close in 0 seconds